Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Conduit Pharmaceuticals Inc. - Common Stock (NQ: CDT )

0.1670 +0.0070 (+4.38%)
Streaming Delayed Price Updated: 12:32 PM EDT, Aug 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Conduit Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 Next >
Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?
Conduit Pharmaceuticals stock is up on Wednesday alongside heavy trading following an invest update on CDT shares. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the biggest stories traders need to know about this morning! 
Via InvestorPlace
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024
Conduit Pharmaceuticals just reported results for the second quarter of 2024. 
Via InvestorPlace
Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?
Conduit Pharmaceuticals stock is up on Thursday with heavy trading of CDT shares after the company announce a new license agreement. 
Via InvestorPlace
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
From Conduit Pharmaceuticals
Via GlobeNewswire
S&P 500 Gains 1%; US Jobless Claims Fall To 230,000
Via Benzinga
Topics Stocks
Exposures US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to dive into the biggest pre-market stock movers on Thursday morning with all of the latest news this morning! 
Via InvestorPlace
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
From Conduit Pharmaceuticals
Via GlobeNewswire
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
Conduit Pharmaceuticals has entered an exclusive licensing agreement with AstraZeneca to develop AZD1656, AZD5658, and AZD5904, targeting autoimmune disorders and idiopathic male infertility. Conduit... 
Via Benzinga
Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
What Happened With Conduit Pharmaceuticals (CDT) Stock Today?
Conduit Pharmaceuticals shares traded higher by over 50% early Tuesday. The company announced it received patent approval for its lead asset targeting autoimmune diseases. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Greenpro Capital (GRNQ) Stock Down 19% Today?
Greenpro Capital stock is down on Tuesday after shares of GRNQ underwent a major rally Monday with the announcement of a strategic alliance. 
Via InvestorPlace
Why Is Autonomix Medical (AMIX) Stock Down 17% Today?
Autonomix Medical stock is down on Tuesday but that's only due to AMIX shares coming off of a massive 130% rally on Monday. 
Via InvestorPlace
Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?
Conduit Pharmaceuticals stock is up with heavy trading of CDT shares on Tuesday after the company secured a new patent in Australia. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning! 
Via InvestorPlace
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Composition of matter patent approval underscores the Company’s solid-form technology to maximize future value and ability to strengthen and broaden its intellectual property portfolio 
From Conduit Pharmaceuticals
Via GlobeNewswire
Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Conduit Pharmaceuticals to Join Russell 3000® Index
From Conduit Pharmaceuticals
Via GlobeNewswire
A Presidio Property Trust Major Investment To Be Part of Russell 2000®
From Presidio Property Trust, Inc.
Via GlobeNewswire
CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q1 2024
Conduit Pharmaceuticals just reported results for the first quarter of 2024. 
Via InvestorPlace
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Conduit Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones index gaining around 80 points on Thursday. Shares of NeoGenomics, Inc. (NASDAQ: NEO) shares fell sharply during Thursday’s session after Natera won a... 
Via Benzinga
Topics Intellectual Property Lawsuit Stocks
Exposures Financial Intellectual Property Legal
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.